| JOURNAL HOME | CME HOME | THIS MONTH | PAST ISSUES | ETOC | COLLECTIONS |
| AUTHORS | REVIEWERS | EDITORIAL BOARD | FEEDBACK | RSS | HELP |
| ||||||||||||||
| ||||||||||||||
|
|
|
|
||||||||||||
|
||||||||||||||
Departments of
*Anesthesiology and Intensive Care,
Orthopedic Surgery,
Clinical Chemistry, Örebro Medical Center Hospital; and
§Department of Statistics, University of Örebro, Örebro, Sweden
Address correspondence and reprint requests to Gustav Ekbäck, MD, Department of Anesthesiology and Intensive Care, Örebro Medical Center Hospital, S-701 85 Örebro, Sweden.
Intraoperatively administered, tranexamic acid (TA) does not reduce bleeding in total hip replacement (THR). Therefore, its prophylactic use was attempted in the present study because this has been shown to be more effective in cardiac surgery. We investigated 40 patients undergoing THR in a prospective, randomized, double-blinded study. Twenty patients received TA given in two bolus doses of 10 mg/kg each, the first just before surgical incision and the second 3 h later. In addition, a continuous infusion of TA, 1.0 mg · kg-1 · h-1 for 10 h, was given after the first bolus dose. The remaining 20 patients formed a control group. Both groups used preoperative autologous blood donation and intraoperative autotransfusion. Intraoperative bleeding was significantly less (P = 0.001) in the TA group compared with the control group (630 ± 220 mL vs 850 ± 260 mL). Postoperative drainage bleeding was correspondingly less (P = 0.001) (520 ± 280 vs 920 ± 410 mL). Up to 10 h postoperatively, plasma D-dimer concentration was halved in the TA group compared with the control group. One patient in each group had an ultrasound-verified late deep vein thrombosis. In conclusion, we found TA, administrated before surgical incision, to be efficient in reducing bleeding during THR.
Implications: In a prospective, double-blinded study of 40 patients undergoing total hip replacement, the preoperative administration of tranexamic acid reduced bleeding by 35%, probably by decreasing induced fibrinolysis. Whether tranexamic acid therapy can replace predonation of autologous blood or intraoperative autotransfusion requires further study.
This article has been cited by other articles:
|
|
 |
|
  A R Ramezani, H Ahmadieh, A K Ghaseminejad, S Yazdani, and B Golestan Effect of tranexamic acid on early postvitrectomy diabetic haemorrhage; a randomised clinical trial Br. J. Ophthalmol., August 1, 2005; 89(8): 1041 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yamasaki, K. Masuhara, and T. Fuji Tranexamic Acid Reduces Postoperative Blood Loss in Cementless Total Hip Arthroplasty J. Bone Joint Surg. Am., April 1, 2005; 87(4): 766 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Mahdy and N. R. Webster Perioperative systemic haemostatic agents Br. J. Anaesth., December 1, 2004; 93(6): 842 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lemay, J. Guay, C. Cote, and A. Roy Tranexamic acid reduces the need for allogenic red blood cell transfusions in patients undergoing total hip replacement: [L'acide tranexamique reduit les besoins de transfusion sanguine allogenique chez les patients devant subir une arthroplastie totale de la hanche] Can J Anesth, January 1, 2004; 51(1): 31 - 37. [Abstract] [Full Text] [PDF]
|
|
|
